At a glance
- Originator Eli Lilly and Company
- Class Small molecules; Sulfonylureas
- Mechanism of Action NADH oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 06 Jun 2001 Discontinued-Preclinical for Cancer in USA (Transdermal)
- 07 Feb 1996 The WHO and EphMRA ATC codes for cancer are L01A and L1A, respectively